LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity

doi:10.3748/wjg.v32.i18.114713

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 18

This Article

(49)

(23)

(0)

(1199)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 14, 2026; 32(18): 114713
Published online May 14, 2026. doi: 10.3748/wjg.v32.i18.114713

Full Size Figure Download Figure

Figure 6 Detection of essential drug resistance-associated genes. A: Protein-protein interaction networks for differentially expressed genes; B: Expression of key genes in tumor and normal tissues from GSE53625; C: LGALS1 expression across all epithelial cells; D: Pseudotime analysis of all malignant epithelial cells, with red indicating the starting point of cell development; E: Distribution of neoadjuvant chemoradiotherapy and surgery groups along cell developmental trajectories; F: Distribution of LGALS1. ^dP < 0.0001. NeoCRT: Neoadjuvant chemoradiotherapy.

Citation: Yan QH, Xu CD, Li ZG, Zheng YZ, Wong WS, Liang DC, Yang J, Chang WG, Wang JY. LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity. World J Gastroenterol 2026; 32(18): 114713
URL: https://www.wjgnet.com/1007-9327/full/v32/i18/114713.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i18.114713

Yan QH, Xu CD, Li ZG, Zheng YZ, Wong WS, Liang DC, Yang J, Chang WG, Wang JY. LGALS1 drives chemoresistance in esophageal squamous cell carcinoma by modulating epithelial-mesenchymal transition and tumor immunity. World J Gastroenterol 2026; 32(18): 114713 [DOI: 10.3748/wjg.v32.i18.114713]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.